GT Medical Technologies raised $37 million in a Series D funding round led by Evidity Health Capital to advance the expansion of GammaTile for brain tumor treatment.
GT Medical Technologies raised $37 million in a Series D funding round led by Evidity Health Capital to advance the expansion of GammaTile for brain tumor treatment.
01/16/25, 1:03 PM
Location
tempeMoney raised
$37 million
Industry
health care
medical
biotechnology
Round Type
series d
Investors
Medtech Venture Partners, Gilde Healthcare, Mvm Partners, Accelmed Partners, Evidity Health Capital
GT Medical Technologies has completed a $37 million Series D financing round, which will accelerate clinical studies and support the commercialization of its GammaTile product. The round was led by Evidity Health Capital and included participation from several other investors.
Company Info
Location
1809 s holbrook lane, suite 107
tempe, arizona, united states
Additional Info
GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 1000+ patients with brain tumors.